How effective is Erdafitinib?
Erdafitinib (Erdafitinib) is an anti-cancer drug with the trade name Balversa. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used to treat cancer. FGFRs are a subset of tyrosine kinases that are unregulated in some tumors and affect tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.

In an open-label Phase 2 study, patients with locally advanced, unresectable, or metastatic urothelial carcinoma and prespecified FGFR alterations were enrolled. All patients had a history of disease progression during or after at least one course of chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy.
A total of99 patients in the selected regimen group received a median of 5 cycles of erdafitinib. Of these patients, 43% had received at least two prior courses of therapy, 79% had visceral metastases, and 53% had creatinine clearance less than 60 milliliters per minute. The confirmed response rate with erdafitinib was 40% (3% complete response, 37% partial response). Among 22 patients who had previously received immunotherapy, the confirmed response rate was 59%. The median progression-free survival was 5.5 months and the median overall survival was 13.8 months. 46%of patients reported Grade 3 or higher treatment-related adverse events, which were mainly controlled through dose adjustment; 13%of patients discontinued treatment due to adverse events, and there were no treatment-related deaths.
The use of erdafitinibis associated with an objective tumor response in 40%of previously treated patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations. The ingredients and doses of generic drugs are the same as those of original drugs, but the price is favorable. Each box of generic drugs is about 2more than more than . If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)